Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CV301 + Atezolizumab in Advanced Bladder Cancer
NCT03628716Phase 2Completed
- Sponsor
- Bavarian Nordic
- Start
- Sep 2018
- Primary completion
- Nov 2020
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CV301 in Urothelial Bladder Cancer (UBC), sponsored by Bavarian Nordic. Primary endpoint: Objective Response Rate up to 24 months. Started Sep 2018; status: completed.
02
Drugs
CV301
03
Conditions
Urothelial Bladder Cancer (UBC)
Beyond the preview
Go deeper on NCT03628716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03628716.